X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Sequencing 101: The Evolution of DNA Sequencing Tools

Wednesday, March 25, 2020

Welcome to the Sequencing 101 blog series – where we will provide introductions to sequencing technology, genomics, and much more!

If you’re not immersed in the field of DNA sequencing, it can be challenging to keep up with the rapid evolution among all the platforms and technologies on the market. Let’s start with a quick overview of how these different technologies came about — and how each is used today.

The evolution of sequencing technology.

 

First Generation Sequencing – Starting the Era of Genomics

The process of Sanger sequencing

The process of Sanger sequencing.

DNA sequencing as we know it originated in the late 1970s, when Frederick Sanger at the MRC Centre in Cambridge developed a gel-based method that combined a DNA polymerase with a mixture of standard and chain-terminating nucleotides, known as ddNTPs. Mixing dNTPS with ddNTPs causes random early termination of sequencing reactions during PCR. Four reactions are run, each with the chain-terminating version of only one base (A, T, G or C). When visualized with gel electrophoresis, one reaction per lane, the fragments are sorted by length, allowing the DNA sequence to be read off base by base. This technique was revolutionary at the time, enabling sequencing of 500-1000 bp fragments. However, since the original method used radioactive ddNTPs and X-rays, it was less than ideal for widespread use.

By the 1980s, Sanger’s original method had been automated by scientists at Caltech and commercialized by Applied Biosystems. Radioactive ddNTPs were replaced with dye-labelled nucleotides and large slab gels were replaced with acrylic-finer capillaries. Scientists could now simply feed prepared DNA into a machine and view the results of fluorescence-based reactions on an electropherogram. This technology, which was continuously improved over the years, served as the bedrock of the Human Genome Project. Today, automated Sanger sequencing is still in use, primarily in clinical labs where it is acceptable to have low throughput, higher per-sample costs, and sequencing reads 500-1,000 bp in length.

But even after the Human Genome Project, the cost of automated Sanger sequencing — also known as capillary electrophoresis — remained too high to enable the kind of large-scale sequencing projects envisioned by scientists. By the mid-2000s, remarkable efforts had been made to bring down the costs of sequencing. Driven largely by grants from the National Human Genome Research Institute (NHGRI), labs around the world tested out new methods for higher-throughput sequencing, using concepts as diverse as electronics, physics, and magnetics.

 

Second Generation Sequencing – Short Reads Become Fast and Efficient

One key player in the advent of next-generation sequencing (NGS) was a UK-based company called Solexa, which was later acquired by Illumina. The key innovation of the Illumina platform was ‘bridge amplification’ which allows the formation of dense clusters of amplified fragments across a silicon chip. Amplification of the original single molecule into a large cluster of many copies is what makes it possible to detect a fluorescent signal as a single dNTP is added one at a time, as sequencing proceeds by synthesis. Over time, the number of clusters that could be read simultaneously grew tremendously, and Illumina instruments became the first commercially available massively parallel sequencing technology. Other tools developed around the same time, such as the Ion Torrent platform, became part of the NGS landscape as well. NGS platforms are the dominant type of sequencing technology used today. Their extreme capacity allows for sequencing at very low cost. They are limited, however, in read length; NGS platforms typically produce reads of ~50-500 bp in length. This makes them an excellent fit for resequencing projects, SNP calling, and targeted sequencing of very short amplicons.

 

Third Generation Sequencing – The Rise of Long Reads

However, short reads are not suitable for all sequencing projects. Another approach that was supported by the so-called $1,000 genome grants from NHGRI was Single Molecule, Real-Time (SMRT) Sequencing from PacBio. This technique uses miniaturized wells, known as zero-mode waveguides, in which a single polymerase incorporates labeled nucleotides and light emission is measured in real time. A different single-molecule approach to long-read sequencing, using pore-forming proteins and electrical detection, was adopted by Oxford Nanopore Technologies (ONT).

 

Watch this short video to learn how SMRT Sequencing works.

 

SMRT Sequencing has a number of advantages. Most notable, perhaps, is its ability to produce long reads — tens of thousands of bases long in a single read. These long reads make it possible to span large structural variants and challenging repetitive regions that confound short-read sequencers because their short snippets cannot be differentiated from each other during assembly. Another advantage is low GC bias, which allows PacBio Systems to sequence through extreme-GC at AT regions that cannot be amplified during cluster generation on short read platforms. A third advantage is the ability to detect DNA methylations while sequencing, since no amplification is done on the instrument.

 

Short-read sequencing compared to highly accurate long-read sequencing

Short-read sequencing produces reads 50-500 base pairs in length, which can lead to sequence gaps and incomplete assemblies, known as draft genomes. Highly accurate long-read sequencing from PacBio produces reads tens of kilobases in length, creating overlaps which allow for the generation of complete genome assemblies.

 

As scientists began to work with SMRT Sequencing — sometimes known as third-generation sequencing — they realized that it had particular value for applications including de novo genome sequencing, phasing, detection of structural variants, epigenetic characterization, and sequencing of the transcriptome without the need for assembly. Technology improvements over time increased the throughput and accuracy of SMRT Sequencing platforms, bringing their costs in line with NGS platforms for many types of projects. Now, SMRT Sequencing has industry-leading accuracy thanks to its HiFi sequencing, and it is being used around the world to produce reference-grade genomes for microbes, plants, animals, and people.


Explore other posts in this series:

Subscribe for blog updates:

Archives